IPO
Brings total raised in the Series E round to $276 million
Spherix’s investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%. The recently announced asset-purchase agreement of CBM BioPharma extends pipeline promise.
Zomedica Pharmaceuticals Corp. announced that it has completed its second tranche closing of Series 1 Preferred Shares with the issuance of 7 Series 1 Preferred Shares to an accredited investor under a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share for a total purchase price of $7,000,000.
Global Blood Therapeutics, Inc. announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the company’s common stock with a per share exercise price of $60.78 and restricted stock units for an aggregate of 96,700 shares of the company’s common stock.
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.
Frontage Holdings Corporation, the parent company of Frontage Laboratories, Inc., a fast-growing contract research organization, specializing in R&D product development services, with operations in both the United States and China, announced on May 30th that the Company’s Shares have initiated trading on the Main Board of The Stock Exchange of Hong Kong.
Amarantus Bioscience Holdings, Inc. released a letter to shareholders from President & CEO Gerald E. Commission
Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences
Founded in 2009 by brothers Chad and Harlan Robins, the company utilizes high-throughput gene sequencing with computer infrastructure that allows scientists to minutely analyze T-cell receptors.
PRESS RELEASES